Intellipharmaceutics International Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2013 to Q4 2022

Taxonomy & unit
us-gaap: CAD and USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Intellipharmaceutics International Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2013 to Q4 2022.
  • Intellipharmaceutics International Inc. Share-based Payment Arrangement, Expense for the quarter ending November 30, 2022 was $0.000.
  • Intellipharmaceutics International Inc. Share-based Payment Arrangement, Expense for the twelve months ending November 30, 2022 was $0.000, a 100% decline year-over-year.
  • Intellipharmaceutics International Inc. annual Share-based Payment Arrangement, Expense for 2022 was $0.000, a 100% decline from 2021.
  • Intellipharmaceutics International Inc. annual Share-based Payment Arrangement, Expense for 2021 was $12K, a 83.3% decline from 2020.
  • Intellipharmaceutics International Inc. annual Share-based Payment Arrangement, Expense for 2020 was $71.6K, a 72.9% decline from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $0 $0 $0 Sep 1, 2022 Nov 30, 2022 20-F/A 2024-02-06
Q3 2022 $0 $0 $0 Jun 1, 2022 Aug 31, 2022 6-K 2022-10-14
Q2 2022 $0 $0 -$1.44K -100% Mar 1, 2022 May 31, 2022 6-K 2022-07-21
Q1 2022 $1.44K $0 -$10.6K -100% Dec 1, 2021 Feb 28, 2022 6-K 2022-04-14
Q4 2021 $12K $0 +$7.22K Sep 1, 2021 Nov 30, 2021 20-F/A 2024-02-06
Q3 2021 $4.77K $0 -$12.9K -100% Jun 1, 2021 Aug 31, 2021 6-K 2022-10-14
Q2 2021 $17.6K $1.44K -$10.8K -88.3% Mar 1, 2021 May 31, 2021 6-K 2022-07-21
Q1 2021 $28.4K $10.6K -$43.2K -80.4% Dec 1, 2020 Feb 28, 2021 6-K 2022-04-14
Q4 2020 $71.6K -$7.22K -$58.1K -114% Sep 1, 2020 Nov 30, 2020 20-F/A 2024-02-06
Q3 2020 $130K $12.9K -$38.5K -74.9% Jun 1, 2020 Aug 31, 2020 6-K 2021-10-15
Q2 2020 $168K $12.2K -$148K -92.4% Mar 1, 2020 May 31, 2020 6-K 2021-07-15
Q1 2020 $316K $53.7K +$51.5K +2264% Dec 1, 2019 Feb 29, 2020 6-K 2021-04-14
Q4 2019 $265K $50.9K -$756K -93.7% Sep 1, 2019 Nov 30, 2019 20-F/A 2022-05-09
Q3 2019 $1.02M $51.4K +$25.9K +101% Jun 1, 2019 Aug 31, 2019 6-K 2020-10-15
Q2 2019 $995K $160K +$96.9K +154% Mar 1, 2019 May 31, 2019 6-K 2020-07-15
Q1 2019 $898K $2.27K -$29.4K -92.8% Dec 1, 2018 Feb 28, 2019 6-K 2020-05-29
Q4 2018 $928K $807K Sep 1, 2018 Nov 30, 2018 20-F 2021-03-31
Q3 2018 $25.5K -$6.56K -20.4% Jun 1, 2018 Aug 31, 2018 6-K 2019-10-11
Q2 2018 $63.1K -$759K -92.3% Mar 1, 2018 May 31, 2018 6-K 2019-07-10
Q1 2018 $31.7K Dec 1, 2017 Feb 28, 2018 6-K 2019-04-15
Q3 2017 $32.1K Jun 1, 2017 Aug 31, 2017 6-K 2018-10-15
Q2 2017 $822K Mar 1, 2017 May 31, 2017 6-K/A 2018-07-24
Q1 2014 $6.54K -$196K -96.8% Dec 1, 2013 Feb 28, 2014 6-K 2014-04-14
Q1 2013 $203K Dec 1, 2012 Feb 28, 2013 6-K 2014-04-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.